AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive. The study evaluated the tolerability, safety, and efficacy of atogepant (marketed as QULIPTA or AQUIPTA) compared to topiramate for the preventive treatment of migraine in adults.

A clinical researcher in a lab examining a new biopharmaceutical product.

Atogepant is an oral medication taken once daily to prevent migraines. It works by specifically blocking the activity of a natural messenger molecule in the patient’s body called Calcitonin Gene-Related Peptide (CGRP). When CGRP is highly active, it can trigger migraine attacks. Atogepant essentially acts like a “bouncer,” occupying the “receptors” or “docking stations” where CGRP would normally attach. As a result, it prevents CGRP from sending pain signals and significantly reduces how often migraines occur.

According to the published results, atogepant successfully met its primary endpoint. The medication demonstrated fewer treatment discontinuations attributed to adverse events (AEs) than topiramate.

AbbVie Inc. (NYSE:ABBV) is an American biopharmaceutical company with global operations. It discovers, develops, and markets medicines across several therapeutic areas, including immunology, oncology, neuroscience, eye care, and virology. Its major products include Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox, and Vraylar.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Biotech Stocks Screaming a Buy and 13 Best Software Stocks to Buy Now.

Disclosure: None.